Skip to main content
Erschienen in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01.12.2019 | Research article

Antilisterial efficacy of Lactobacillus brevis MF179529 from cow: an in vivo evidence

verfasst von: Ayesha Riaz, Saleha Noureen, Iram Liqat, Muhammad Arshad, Najma Arshad

Erschienen in: BMC Complementary Medicine and Therapies | Ausgabe 1/2019

Abstract

Background

Listeria monocytogenes is an opportunistic foodborne pathogen that causes human Listeriosis and high mortality particularly in immunocompromised individuals. Pregnant women are more prone to L. monocytogenes infection resulting in abortions.
In the present study, antilisterial activity of Lactobacillus brevis (LB) MF179529, a probiotic bacterial strain, was investigated in a murine model.

Methods

Initially a pilot study was conducted to determine the dose of L. monocytogenes required to cause symptomatic listeriosis. In the main trial, mice were divided into 4 groups. Group I was kept as negative control, group II was exposed to L. monocytogenes and maintained as positive control. Group III was fed with L. brevis only, while group IV received L. brevis for 3 days prior to L. monocytogenes infection. A volume of 200 μl of L. monocytogenes ATCC 19115 and L. brevis MF179529 bacterial suspension corresponding to cell density of 109CFU/ml were given to respective groups by intragastric route. Progress of infection was monitored for 7 days including general health scoring, listeria dispersion in organs, bacterial load in intestine and blood biochemistry were recorded on 3rd, 5th and 7th days post infection (dpi).

Results

Clinical listeriosis was induced by 109CFU/ml of L. monocytogenes ATCC 19115 in mice.
Animals of group IV displayed minor signs of infection. L. brevis supplementation resulted in significant reduction in dispersion and propagation of L. monocytogenes in liver, spleen and intestine. L. brevis MF179529 consumption led to a significant elevation of number of lactic acid bacteria and reduction of total plate count, anaerobic count and coliform population in intestine. Moreover, total leukocyte and neutrophil counts of treated animals were similar to the negative control while positive control group displayed higher number. Safety evaluation of L. brevis was performed by monitoring general health, hematological and serological parameters of L. brevis fed and negative control group (group III and I). No significant difference in feed intake, body temperature, body weight and blood picture could be detected in L. brevis supplemented and control groups.

Conclusion

Our results indicate ameliorative role of L. brevis in L. monocytogenes infection and suggest that L. brevis could be used for prophylactic measure.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12906-019-2444-5) contains supplementary material, which is available to authorized users.
Abkürzungen
APC
Anaerobic Plate Count
dpi
day post infection
GHS
General health scoring
Hb
Hemoglobin
LAB
Lactic Acid Bacteria
LB
Lactobacillus brevis MF179529
LM
Listeria monocytogenes LM ATCC19115
NCBI
National Center for Biotechnology Information
TPC
Total Plate Count

Background

Pathogenic microbes are important due to their role in health complications and food spoilage. Listeria monocytogenes (LM) is a facultative intracellular food borne pathogen which is causative agent of human listeriosis, gastrointritous, abortion, meningoencephalits and septicemia [1]. Immuno-compromised individuals, pregnant women and fetus are more prone to listeriosis [2]. Ingestion of LM contaminated food results in translocation of pathogen from intestinal lumen to different organs [3]. Listeriosis is serious public health issue and lead to 20 to 30% mortality [4].
Probiotics are defined as live nonpathogenic microorgansims, when used in adequate amount give health benefits to the host [5]. They play an important role in maintaining the microbial balance in gastrointestinal tract of the host by promoting growth of beneficial microbes and also modulate immune responses [6]. Mostly probiotics belong to a group of Lactic acid bacteria (LAB), among them Lactobacillus and Bifidobacterium genera are used commercially [7, 8]. Probiotic strains use different mechanisms to combat infection viz., production of inhibitory substances, blocking of adhesion sites on the intestinal surface, dislocation of the initially adhered pathogen, competition for nutrients and stimulation of mucosal and systemic immunity [9]. The antagonistic and co-aggregation potential of probiotic strains against pathogen is strain specific [10]. Probiotic supplements are used singly or in combination to combat pathogen but mixture of probiotic strains is reported to be more effective [11]. Probiotics are recommended by health professionals to cure gastroenteritis including mild diarrhea, ulcerative colitis, antibiotic associated diarrhea when standard theropies did not work [12].
Can be used as an alternative to chemical growth promoter, and growth performance of the host. LAB are reported to produce antimicrobial compound such as lactic acid, hydrogen peroxide, reuterin, diacetyl, acetoin reutricyclin, antifungal peptides and bacteriocins [13]. Bacteriocins are small peptides produced as secondary metabolites which have the ability to inhibit the growth of closely related species, allowing competition among different niches. LAB are known to produce fermented products as well as bacteriocins that have the inhibitory effect against clinical and foodborne pathogens including LM [14, 15]. Thus LAB are recommended to be used as food supplement and therapeutic agent against infectious diseases [16].
To the best of our knowledge, this is the first report on antimicrobial efficacy of L. brevis (LB) MF179529 against LM using a murine infection model.

Methods

Bacterial strain & culture conditions

L. brevis (LB) MF179529, a strain previously isolated from fresh cow fecal samples and identified by 16S rRNA sequencing in our laboratory. The bacterial strain was refreshed by plating on de Man Rogosa Sharpe (MRS) agar following incubation at 35 °C for 48 h anaerobically. This strain can be obtained from First Fungal Culture Bank of Pakistan (FCBP) with accession number FCBP-692, a registered World Federation of Culture Collections WFCC) in Pakistan. Listeria monocytogenes (LM) ATCC 19115 was obtained from the American Type Culture Collection. LM ATCC 19115 strain was cultivated in Tryptic Soya Broth (TSB) supplemented with 0.6% (w/v) yeast extract at 37 °C for 24 h. Both strains were preserved in 20% glycerol stocks at − 80 °C and were revived by sub culturing from glycerol stock whenever required.

Preparation of inoculum

LB and LM were grown in de Man Rogosa Sharpe (MRS) and Tryptic Soya Broth (TSB) respectively for specified time period. In order to select the infectious bacterial density, overnight culture of LM was centrifuged and pellet was washed thrice with 0.01 M sterile Phosphate Buffered Saline (PBS) buffer (pH 7). Pellet was re-suspended in sterile 0.01 M PBS buffer, OD was adjusted to 1 ± 0.05 at 600 nm. Three doses were used in pilot study viz, 105,107 and 109 CFU/ml and bacterial density of LM corresponding to 109 CFU/ml was selected as infectious dose to be used in the main experiment .

Animals

Healthy albino male mice (Mus musculus, 6–8 week old) were purchased from University of Veterinary and Animal Sciences, Lahore and acclimatized in animal house of Department of Zoology, University of the Punjab, Lahore, for one week prior to experimentation. Mice were kept in temperature controlled environment at 28 ± 2 °C with photoperiod 12 h light/dark cycles, humidity 30–35%. They were housed in standard sized cages (12 ″ × 18″ inches) whereas basal diet and fresh water were provided ad libitum.

Determination of listeria dose (pilot study)

The bacterial density of LM required to induce infection was determined in a pilot study. Mice (n = 24) were divided into 4 groups at random, group A, B and C were inoculated once with 200 μl of LM suspension corresponding to cell density of 105, 107 and 109 CFU/ml respectively through intragastric gavage. Group D was maintained as negative control and treated similarly with equal volume of 0.01 M sterile PBS. Re-isolation of LM from visceral organs (spleen, liver and intestine) was used as a criterion of induction of listeriosis. The bacterial density which led to dispersion of LM in liver, spleen and intestine of all animals was used to induce infection in the main study.

In vivo efficacy and safety of L. brevis

A total of 60 mice were divided in four groups I-IV. Groups I and II were used as negative and positive control respectively, group III received only L. brevis while group IV received both LB and LM. Mice were fed with L. brevis (109 CFU/ml/ mouse) orally by intragastric gavage for 3 consecutive days before oral infection with L. monocytogene. Sampling was performed at 3rd, 5th and 7th day of post infection.

General health scoring (GHS)

Mice were observed daily for clinical signs and symptoms of infection, including animal movement, fur condition, structure of backbone, dehydration and feeding activity and symptoms were scored from 0 to 4. The scores represent following physical attributes (0) Active, alert showing no sign of discomfort; (1) Active, ruffled fur beginning; (2) Slow, ruffled fur with pronounced circumflexed back; (3) Sluggish, ruffled fur, circumflexed back, skin lesion; (4) Sluggish, ruffled fur, circumflexed back, closed and sunken eyes, difficulty in feeding. Animals were scored daily for their health conditions upto 7 days post infection. The GHS of infected animals (II) group were compared with LB treated group (IV).

Temperature, body weight and feed intake measurements

The body temperature and body weight of each animal was monitored daily throughout the experiment using rectal thermometer and balance (SHIMADZU -ELB300). Similarly, feed intake of each animal was monitored and measured by subtracting feed left behind from the feed given and dividing it by number of the animals in the group.

L. monocytogenes load in different organs

Total 5 mice from each group were sacrificed following ULAM guide lines of euthanization by intra peritoneal injection of ketamine (200 mg/kg of body weight) on 3rd, 5th and 7th day post infection (dpi). Quantification of LM in tissues was performed by removing liver, spleen and intestine aseptically from slaughtered mice. Dilutions of weighed amount of tissue homogenate were prepared in sterile 0.01 M PBS and plated on lithium chloridephenylethanol-moxalactam (LPM) agar for the determination of LM count per gram of the tissue.

Intestinal bacterial composition

Assessment of intestinal microbial composition of all groups was done by enumerating coliform, Lactic Acid Bacteria (LAB), Total Plate Count (TPC) and Anaerobic Plate Count (APC) on selective media; MacConkey, MRS, nutrient agar under aerobic condition and nutrient agar under anaerobic condition respectively.

Hematological and serological analysis

Blood was collected by cardiac puncture and kept in EDTA coated and uncoated vails for hematological and serological analysis respectively. For differential leucocytes counting blood smear was prepared on glass slide and fixed with 100% methanol for 5 min. Later on, it was stained with Writght-Giemsa stain for 10 min. Slides were analyzed for lymphocytes, neutrophils, monocytes and eosinophils counts under oil immersion. Serum analysis was performed through fully automated analyzers (Olympus-AU400, USA) using chemical reagents of Beckmann coulter, serum parameters included ALP, ALT/SGPT, AST/SGOT, TBil, Urea, Creatinine, CHOl, TG, HDL and LDL.

Statistical analysis

Statistical analysis was performed using IBM SPSS software (Statistical Package for Social Sciences) version 21 Chicago, IL, USA. Experiments were performed in triplicate from each sample. All results are presented as group means ± S.E. One Way ANOVA followed by Tukey’s test, independent sample t test and Mann-Whitney U tests were performed as and where appropriate. The p value < 0.05 was considered significant.

Results

The probiotic strain used in the study was Gram positive rod, non-spore former, non-motile and catalase negative. It was identified as Lactobacillus brevis on the basis of 16S rRNA sequencing and assigned accession number MF179529 by National Center for Biotechnology Information (NCBI). In pilot study, LM could not be re-isolated from tissues including liver, spleen and intestine of animals exposed to lower bacterial density (105 CFU/ml). Animal exposed to a dose of 107 CFU/ml showed presence of LM in few tissues. It was reisolated from liver and intestine of 2/6 and spleen of 1/6 animals. A single intragastric dose of 109CFU/ml of LM resulted in translocation of pathogen in all tissues of sacrificed animals (Table 1).
Table 1
Effect of different doses of LM ATCC19115 on establishment of infection, survival and re-isolation frequency in mice
Parameter
Groups (Dose CFU/ml)
A (109)
B (107)
C (105)
D (NIL)
Mortality
0/6
0/6
0/6
0/6
Re-solation
 Liver
6/6
2/6
0/6
0/6
 Spleen
6/6
1/6
0/6
0/6
 Intestine
6/6
2/6
0/6
0/6
The denominator showed the total number of animals and numerators showed animals exhibiting the respective parameters
In the main study, protective effect of orally administered LB MF179529 (109CFU/ml) against Listeria infection (109 CFU/ml) was monitored. General health conditions of LB fed group were better than positive control group (P ≤ 0.05). The comparison of GSH scores in LB treated and infected group (IV and II) is presented in Table 2.
Table 2
Comparison of GHS of LM infected and LB + LM treated group
DPI
Group
General health score
Mann-Whitney U test
0
1
2
3
4
Mean rank
P value
Day1
Infection
15/15
0/15
0/15
0/15
0/15
0
1.00
Treated
15/15
0/15
0/15
0/15
0/15
0
Day2
Infection
0/15
9/15
6/15
0/15
0/15
16.2
.007
Treated
9/15
6/15
0/15
0/15
0/15
8.2
Day3
Infection
0/15
3/15
6/15
4/15
2/15
12.5
.005
Treated
12/15
3/15
0/15
0/15
0/15
4.5
Day4
Infection
0/10
0/10
3/10
4/10
3/10
10.5
.001
Treated
10/10
0/10
0/10
0/10
0/10
3
Day5
Infection
0/10
0/10
2/10
2/10
6/10
10.5
.001
Treated
10/10
0/10
0/10
0/10
0/10
3
Day6
Infection
0/5
0/5
1/5
0/5
4/5
8
.001
Treated
5/5
0/5
0/5
0/5
0/5
2
Day7
Infection
0/5
0/5
0/5
1/5
4/5
8
.001
Treated
5/5
0/5
0/5
0/5
0/5
2
GHS was compared using Mann-Whitney U test among infection and treated groups by mean rank values. Significant (P < 0.05) values were observed within 2 groups after 7 days of post infection
Initial body weight among groups was between 30 to 34 g. Among groups there was no significant difference in body weight of animals at the start of experiment. During course of experiment the body weight of negative control (I) and LB fed (III) group remained unaltered, while continuous decrease was observed in positive control (II) group where it reduced from 34 to 28 g. LM + LB treated group (IV) showed initial decrease in body weight at 3rd dpi but later on it increased to level of negative control (Additional file 1: Figure S1). Feed intake of positive control group (II) also decreased in comparison with all other groups (Additional file 2: Figure S2). Body temperature of negative control and LB fed animals (I and III) group remained normal throughout the experiment. Body temperature of LB + LM group (IV) increases up to 3rd dpi and then become equal to negative control (I) group. While body temperature remained high in LM group (II) (Fig. 1).
Data on LM translocation in organs revealed that LM load in liver, spleen and intestine was significantly reduced in LB + LM treated (IV) group as compared to positive control (II) group. LM count of group IV was 4.45 CFU/g, 4.15 CFU/g in liver and 4.45 CFU/g and 4.15 CFU/g in spleen at 3rd and 5th dpi respectively. However, it could not be re-isolated at 7th dpi LM from both tissues. On the other hand, its value was 5.3, 5.1 and 4.8 log CFU/g at 3rd, 5th and 7th dpi respectively in intestine. The LM count in group II remained high in all tissues (4.9–5.1 CFU/g in liver, 4.4–4.6 CFU/g in spleen and 6.7–7.3 log CFU/g in intestine) during course of experiment (Fig. 2).
Influence of LB treatment on the microbial composition of intestine of mice was analyzed by comparing coliform, LAB, TPC and APC count of group I-IV. LB supplementation lead to significant reduction in TPC and coliform count in group III and IV (Fig. 3a and d). However, significant elevation in LAB count was detected in group III and IV. While infection with LM reduced LAB count in group II when compared with negative control group I (Fig. 3b). The anaerobic plate count (APC) was recorded higher in group III while, in other groups it was similar (Fig. 3c). The pattern of change in TPC, APC, LAB and coliform count was similar at all time points (3rd, 5th and 7th dpi).
Effect of LB treatment on course of infection was further determined by comparing hematological picture of the four groups. A significant decrease in hemoglobin (Hb) and elevation in TLC was noticed at 3rd dpi in positive control (II) group. Platelets count of group II also decreased significantly as compared to negative control group. But LB treated groups (III and IV) showed higher platelets count as compared to negative control group. A significant increase in neutrophils and decrease in lymphocytes was also observed in positive control group (II) while no such alteration was observed in LB treated groups (III and IV). The variation in eosinophils and monocytes levels was not significant among groups (p > 0.05) (Table 3). Serological parameters including ALP, ALT/GPT, AST/GOT, TBil, Urea, creatinine, CHOL, TG, HDL and LDL were analyzed during experiment at 3rd, 5th and 7th dpi. No significant change was observed in serological parameters of infected and uninfected groups (data not mentioned).
Table 3
Effect of L.brevis on the course of listeria infection: changes in hematological parameters
Parameters
dpi
Control
Infection
L.brevis
Treated
HB(g/dl)
3
12.7 ± 0.7a
10.1 ± 0.2b
12.8 ± 0.1a
11.6 ± 0.5ab
5
12 ± 0.58ab
11.6 ± 0.23b
13.37 ± 0.38a
12.53 ± 0.20ab
7
12.67 ± 0.67
10.70 ± 0.10
13.20 ± 0.42
11.97 ± 0.55
TLC(X1000)
3
4.75 ± 1.26b
7.4 ± 1.0a
5.03 ± 2.6b
4.9 ± 2.17b
5
4.96 ± 2.60ab
5.033 ± 1.33ab
5.8 ± 2.08a
4.53 ± 3.76b
7
4.70 ± 2.89
5.77 ± 1.33
4.77 ± 145.30
5.33 ± 3.84
Platelets
3
566.3 ± 16.8b
378.3 ± 25.5c
707.7 ± 36.4a
760.0 ± 27.6a
5
565 ± 17a
436 ± 34b
613 ± 11a
661 ± 37a
7
572.00 ± 14.01a
472.67 ± 20.73b
627.33 ± 15.07a
646.33 ± 25.8a
Neutrophils %
3
14.3 ± 0.3b
26.3 ± 0.7a
12.3 ± 1.8b
16.0 ± 1.6b
5
14 ± 0.58b
22.67 ± 1.76a
12.33 ± 1.45b
15.33 ± 0.67b
7
13.67 ± 0.88b
24.00 ± 2.00a
13.33 ± 1.20b
13.00 ± 0.58b
Lymphocytes %
3
76.7 ± 1.8bc
71.0 ± 1.0c
85.7 ± 0.9a
80.3 ± 1.7ab
5
83 ± 1.53a
74.67 ± 2.03b
86 ± 1.00a
81.33 ± 0.67a
7
80.00 ± 1.15
74.67 ± 2.73
80.00 ± 2.31
81.67 ± 1.45
Monocytes %
3
1.7 ± 0.7
2.0 ± 0.0
2.7 ± 0.3
3.0 ± 0.4
5
1.33 ± 0.33
2.00 ± 0.00
2.33 ± 0.33
2.00 ± 0.00
7
2.33 ± 0.33
2.00 ± 0.58
2.00 ± 0.58
2.67 ± 0.33
Eosinophils %
3
1.3 ± 0.3
0.7 ± 0.3
1.0 ± 0.6
0.8 ± 0.3
5
1.67 ± 0.67
0.67 ± 0.33
1.00 ± 0.00
1.33 ± 0.67
7
1.33 ± 0.33
1.00 ± 0.58
1.00 ± 0.58
1.33 ± 0.33
Analysis was performed using one-way ANOVA followed by DMRT. Values in rows having no common letter in superscript are significantly different from each other. Data was presented in term of mean ± SE, P values < 0.05 were considered significant

Discussion

Listeria monocytogenes is a worldwide public health threat and cause listeriosis by consumption of contaminated food. The current study was performed to comprehend the impact of Lactobacillus brevis MF179529 against orally acquired Listeriosis in mice.Listeria monocytogenes ATCC 19115 was chosen as a model of bacterial infection in mice. First obstacle in the study was the establishment of LM ATCC 19115 infection in mice. The bacterial density of pathogen for induction of infection varies depending on virulence of strain, route of exposure and dose of pathogen [17]. Since LM is not acid tolerant and most likely to be killed due to low pH in stomach [18]. Higher bacterial density of pathogen is required to induce infection through oral route as compared to intraperitoneal and subcutaneous. Previously, various authors reported successful infection in experimental animals at the dose of 109 of LM [1921]. Therefore, a pilot study was conducted to determine the infective dose of LM ATCC 19115 using oral transmission route. The oral route was preferred due to its mimicry with human fecal oral route of Listeriosis [22]. Mice were infected with LM ATCC 19115 at three doses (200 μl of 0, 105, 107, 109 CFU/ml) and monitored for morbidity as well as mortality up to 7 dpi. Mice receiving 109CFU/ml displayed clinical signs of infection including circumflex back, ruffled fur and sluggish movement. Additionally, LM was successfully re-isolated from liver, spleen and intestine indicating successful establishment of clinical infections and dissemination of pathogens. On the other hand, in animals exposed to dose of 107 CFU/ml, re-isolation frequency was very low indicating slight infection. In light of these results bacterial density of 109 CFU/ml was decided for main study.
In an effort to analyze the protective effect of local strain L. brevis MF179529 against LM ATCC 19115 infection in mice, main study was conducted. Previously, most of the literature reports the inhibitory effects of Pediococcus acidilactici, Lactobacillus casei, Lactobacillus brevis and Lactobacillus paracasei on LM. L. brevis MF179529 was one of our lab isolates with significant antimicrobial activity against both Gram positive and Gram negative pathogenic isolates (data not shown). To the best of our knowledge, no data exists on antilisterial effect of LB.
On the basis of previous literature on LAB species, 200 μl of 109 CFU/ml bacterial density of LB MF179529 was offered to mice three days prior to LM infection. [23, 24]. A significant reduction in general health score (GHS) of LB treated animals was noticed throughout. LB treated groups manifested a significant increase in feed intake and gain in body weight as compared to positive control. Likewise, body temperature of LB treated group remained high up to 3 dpi and later on dropped to normal level. These positive effects may be due to limiting growth or dissemination of LM, or change in intestinal microbial equilibrium by LB.
To further strengthen the role of LB in decreasing LM infection, the pathogen load in different organs was quantified. LB treated group displayed low tissue invasion in liver, spleen and intestine relative to positive control group. Interestingly, complete elimination of pathogen was noticed in liver and spleen at 7th dpi. Consistently, LM counts in intestinal tract also reduced gradually from 3rd to 7th dpi, although it was not totaly eliminated. It may be due to secretions of antimicrobial compounds, competition among LB and LM for colonization in GI tract etc. Our findings are consistent with Becattini et al. [25] who reported that commensal gut microbiota play a defensive role against LM infection by preventing its systemic dissemination. Our results are in accordance with previous observations on reduction of LM count among liver, spleen and intestine by pre feeding with Lactobacillus casei [2629].
Of note, another important contribution of LB MF179529 consumption on GI tract was noticed by alteration in intestinal microbial equilibrium. A significant increase in lactic acid bacteria along with reduction of other intestinal bacteria including LM proposed antilisterial activity of LB. It may be due to competitive survival of LB in GI tract [30]. Recovery of high quantity of LAB from the intestine further indicates that LB could successfully withstand the stressed conditions of gastrointestinal tract of mice supporting its probiotic nature. In fact, use of LAB to ablate the intestinal pathogens is pertinent to previous observations on the synergistic effects of antibiotics and corticosteroids in listeriosis [31]. Additionally, antilisterial activity of LB may be an outcome of antimicrobial peptide secretion as reported previously [32].
Hematological studies provide important information about multiple disorders including bacterial infections. Phagocytes especially macrophages and neutrophils plays an important role against bacterial infections. To further confirm the remodeling role of LB, the hematological picture of all groups was compared. Our results indicated that Hb level decreased in infection group making it a high risk factor to the health [33]. It is known since long that LM produces soluble hemolysin which causes lysis of erythrocytes and LM utilize the iron present in hemoglobin to thrive in the host [34]. Absence of anemia in LB treated mice (group III and IV) confirms the antilisterial efficiency of our strain. It may be due to absence of hemolysin production by our strain. Further evidence was provided by TLC, neutrophil and platelet count. Increased TLC and neutrophil count along with decreased platelets counts are indication of establishment and persistence of infection [35, 36]. In LB treated group (III and IV) TLC, neutrophil and platelets counts remained equal to negative control. Similarly, lymphocytes count remained unaltered in all groups except infection group where it decreased significantly. This indicates the clinical importance and non-pathogenic nature of LB.
In vivo safety assessment of LB was performed by comparing hematological and serum biochemical profiles in control and LB fed group. No significant variation in any serological parameter could be recorded indicating safe nature of LB MF179529. In culmination, our results suggest that LB MF179529 from cow intestine is useful for prevention of invasion and facilitates suppression of LM ATCC19115 infection in mice.

Conclusion

In the present study, our results indicated that oral administration of LB MF179529 provides protective effect to the Listeria infected mice. LB reduces LM load in liver, spleen and intestine and favorably perturbates intestinal microbial equilibrium. We suggest that LB MF179529 ingestion has health promoting capacities and a good candidate to be employed as a probiotic against listeria infection. Further studies are needed to best understand the mechanisms by which this microorganism promotes resistance against infectious diseases.

Acknowledgements

Authors are thankful to the Department of Zoology, University of the Punjab, Lahore for providing research facilities to prepare this valuable document.

Funding

Authors are grateful to Higher Education Commission Pakistan (HEC) grant No 112–25549-2BMI-570(50022668) for the financial support in this study.

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval

All animals used in the study were handled according to the guide lines of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council (UK) and approved by Animal Ethics Committee, Department of Zoology, University of the Punjab, Lahore.
“Not applicable”.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Barbuddhe SB, Chakraborty T. Listeria as an enteroinvasive gastrointestinal pathogen. Molecular mechanisms of bacterial infection via the gut Springer. 2009:173–95. Barbuddhe SB, Chakraborty T. Listeria as an enteroinvasive gastrointestinal pathogen. Molecular mechanisms of bacterial infection via the gut Springer. 2009:173–95.
2.
Zurück zum Zitat Lecuit M. Human listeriosis and animal models. Microbes Infect. 2007;9:1216–25.CrossRef Lecuit M. Human listeriosis and animal models. Microbes Infect. 2007;9:1216–25.CrossRef
3.
Zurück zum Zitat Quereda JJ, Dussurget O, Nahori MA, Ghozlane A, Volant S, Dillies MA, Regnault B, Kennedy S, Mondot S, Villoing B. Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection. Proc Natl Acad Sci. 2016;113:5706–11.CrossRef Quereda JJ, Dussurget O, Nahori MA, Ghozlane A, Volant S, Dillies MA, Regnault B, Kennedy S, Mondot S, Villoing B. Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection. Proc Natl Acad Sci. 2016;113:5706–11.CrossRef
4.
Zurück zum Zitat Inoue T, Itani T, Inomata N, Hara K, Takimoto I, Iseki S, Hamada K, Adachi K, Okuyama S, Shimada Y. Listeria Monocytogenes septicemia and meningitis caused by Listeria enteritis complicating ulcerative colitis. Intern Med. 2017;56:2655–9.CrossRef Inoue T, Itani T, Inomata N, Hara K, Takimoto I, Iseki S, Hamada K, Adachi K, Okuyama S, Shimada Y. Listeria Monocytogenes septicemia and meningitis caused by Listeria enteritis complicating ulcerative colitis. Intern Med. 2017;56:2655–9.CrossRef
5.
Zurück zum Zitat Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008;46:S58–61.CrossRef Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008;46:S58–61.CrossRef
6.
Zurück zum Zitat Chiang S-S, Pan T-M. Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products. Appl Microbiol Biotechnol. 2012;93:903–16.CrossRef Chiang S-S, Pan T-M. Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products. Appl Microbiol Biotechnol. 2012;93:903–16.CrossRef
7.
Zurück zum Zitat Taheri H, Tabandeh F, Moravej H, Zaghari M, Shivazad M, Shariati P. Potential probiotic of Lactobacillus johnsonii LT171 for chicken nutrition. Afr J Biotechnol. 2009;8:5833–37. Taheri H, Tabandeh F, Moravej H, Zaghari M, Shivazad M, Shariati P. Potential probiotic of Lactobacillus johnsonii LT171 for chicken nutrition. Afr J Biotechnol. 2009;8:5833–37.
8.
Zurück zum Zitat Mishra AK, Ghosh AR. Characterization of functional, safety, and probiotic properties of Enterococcus faecalis AG5 isolated from Wistar rat, demonstrating adherence to HCT 116 cells and gastrointestinal survivability. Probiotics Antimicrob Proteins. 2018;10:435–45. Mishra AK, Ghosh AR. Characterization of functional, safety, and probiotic properties of Enterococcus faecalis AG5 isolated from Wistar rat, demonstrating adherence to HCT 116 cells and gastrointestinal survivability. Probiotics Antimicrob Proteins. 2018;10:435–45.
9.
Zurück zum Zitat Bujalance C, Jiménez-Valera M, Moreno E, Ruiz-López MD, Lasserrot A, Ruiz-Bravo A. Lack of correlation between in vitro antibiosis and in vivo protection against enteropathogenic bacteria by probiotic lactobacilli. Res Microbiol. 2014;165:14–20.CrossRef Bujalance C, Jiménez-Valera M, Moreno E, Ruiz-López MD, Lasserrot A, Ruiz-Bravo A. Lack of correlation between in vitro antibiosis and in vivo protection against enteropathogenic bacteria by probiotic lactobacilli. Res Microbiol. 2014;165:14–20.CrossRef
10.
Zurück zum Zitat Kumar S, Yarla N, Mishra V, Daim M, Sharma B, Ashraf G, Reggi R, Palmery M, Peluso I, Kamal M. Single probiotic versus multiple probiotics-a debate in current scenario for alleviating health benefits. Curr Pharm Design. 2018;24:1–4.CrossRef Kumar S, Yarla N, Mishra V, Daim M, Sharma B, Ashraf G, Reggi R, Palmery M, Peluso I, Kamal M. Single probiotic versus multiple probiotics-a debate in current scenario for alleviating health benefits. Curr Pharm Design. 2018;24:1–4.CrossRef
11.
Zurück zum Zitat McFarland LV, Evans CT, Goldstein EJ. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5(24). McFarland LV, Evans CT, Goldstein EJ. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5(24).
12.
Zurück zum Zitat Sanders ME. Probiotics in 2015: their scope and use. J Clin Gastroenterol. 2015;49:2–6.CrossRef Sanders ME. Probiotics in 2015: their scope and use. J Clin Gastroenterol. 2015;49:2–6.CrossRef
14.
Zurück zum Zitat De Carvalho A. A T,De Paula R a, Mantovani HC, De Moraes C a. Inhibition of Listeria monocytogenes by a lactic acid bacterium isolated from Italian salami. Food Microbiol. 2006;23:213–9.CrossRef De Carvalho A. A T,De Paula R a, Mantovani HC, De Moraes C a. Inhibition of Listeria monocytogenes by a lactic acid bacterium isolated from Italian salami. Food Microbiol. 2006;23:213–9.CrossRef
15.
Zurück zum Zitat Verluyten J, Messens W, De Vuyst L. Sodium chloride reduces production of curvacin a, a bacteriocin produced by Lactobacillus curvatus strain LTH 1174, originating from fermented sausage. Appl Environ Microbiol. 2004;70:2271–8.CrossRef Verluyten J, Messens W, De Vuyst L. Sodium chloride reduces production of curvacin a, a bacteriocin produced by Lactobacillus curvatus strain LTH 1174, originating from fermented sausage. Appl Environ Microbiol. 2004;70:2271–8.CrossRef
16.
Zurück zum Zitat Cao Z, Pan H, Li S, Shi C, Wang S, Wang F, Ye P, Jia J, Ge C, Lin Q. In vitro evaluation of probiotic potential of lactic acid Bacteria isolated from Yunnan De’ang pickled tea. Probiotics Antimicrob Proteins. 2018:1–10. Cao Z, Pan H, Li S, Shi C, Wang S, Wang F, Ye P, Jia J, Ge C, Lin Q. In vitro evaluation of probiotic potential of lactic acid Bacteria isolated from Yunnan De’ang pickled tea. Probiotics Antimicrob Proteins. 2018:1–10.
17.
Zurück zum Zitat Roche S, Gracieux P, Albert I, Gouali M, Jacquet C, Martin P, Velge P. Experimental validation of low virulence in field strains of Listeria monocytogenes. Infect Immun. 2003;71:3429–36.CrossRef Roche S, Gracieux P, Albert I, Gouali M, Jacquet C, Martin P, Velge P. Experimental validation of low virulence in field strains of Listeria monocytogenes. Infect Immun. 2003;71:3429–36.CrossRef
18.
Zurück zum Zitat D'Orazio SE. Animal models for oral transmission of Listeria monocytogenes. Front Cell Infect Microbiol. 2014;4:15.CrossRef D'Orazio SE. Animal models for oral transmission of Listeria monocytogenes. Front Cell Infect Microbiol. 2014;4:15.CrossRef
19.
Zurück zum Zitat Barbour AH, Rampling A, Hormaeche CE. Variation in the infectivity of Listeria monocytogenes isolates following intragastric inoculation of mice. Infect Immun. 2001;69:4657–60.CrossRef Barbour AH, Rampling A, Hormaeche CE. Variation in the infectivity of Listeria monocytogenes isolates following intragastric inoculation of mice. Infect Immun. 2001;69:4657–60.CrossRef
20.
Zurück zum Zitat Czuprynski CJ, Faith NG, Steinberg H. Ability of the Listeria monocytogenes strain Scott A to cause systemic infection in mice infected by the intragastric route. Appl Environ Microbiol. 2002;68:2893–2900. Czuprynski CJ, Faith NG, Steinberg H. Ability of the Listeria monocytogenes strain Scott A to cause systemic infection in mice infected by the intragastric route. Appl Environ Microbiol. 2002;68:2893–2900.
21.
Zurück zum Zitat Corr SC, Li Y, Riedel CU, O'toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci. 2007;104:7617–21.CrossRef Corr SC, Li Y, Riedel CU, O'toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci. 2007;104:7617–21.CrossRef
22.
Zurück zum Zitat Park JH, Park Y, Seok S, Cho S, Kim D, Lee H, Kim S, Park J. Suppurative gastritis in BALB/c mice infected with Listeria monocytogenes via the intragastric route. J Comp Pathol. 2004a;130:130–6.CrossRef Park JH, Park Y, Seok S, Cho S, Kim D, Lee H, Kim S, Park J. Suppurative gastritis in BALB/c mice infected with Listeria monocytogenes via the intragastric route. J Comp Pathol. 2004a;130:130–6.CrossRef
23.
Zurück zum Zitat De Waard R, Garssen J, Bokken G, Vos J. Antagonistic activity of Lactobacillus casei strain Shirota against gastrointestinal Listeria monocytogenes infection in rats. Int J Food Microbiol. 2002;73:93–100.CrossRef De Waard R, Garssen J, Bokken G, Vos J. Antagonistic activity of Lactobacillus casei strain Shirota against gastrointestinal Listeria monocytogenes infection in rats. Int J Food Microbiol. 2002;73:93–100.CrossRef
24.
Zurück zum Zitat Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I. In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Int J Food Microbiol. 2009;133:225–33.CrossRef Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I. In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Int J Food Microbiol. 2009;133:225–33.CrossRef
25.
Zurück zum Zitat Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. BioPsychoSoc Med. 2012;6:1–8. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. BioPsychoSoc Med. 2012;6:1–8.
26.
Zurück zum Zitat Park JH, Park Y, Seok S, Cho S, Kim D, Lee H, Kim S, Park J. Suppurative gastritis in BALB/c mice infected with Listeria monocytogenes via the intragastric route. J Comp Pathol. 2004b;130:130–6.CrossRef Park JH, Park Y, Seok S, Cho S, Kim D, Lee H, Kim S, Park J. Suppurative gastritis in BALB/c mice infected with Listeria monocytogenes via the intragastric route. J Comp Pathol. 2004b;130:130–6.CrossRef
27.
Zurück zum Zitat Archambaud C, Nahori MA, Soubigou G, Bécavin C, Laval L, Lechat P, Smokvina T, Langella P, Lecuit M, Cossart P. Impact of lactobacilli on orally acquired listeriosis. Proc Natl Acad Sci. 2012;109:16684–9.CrossRef Archambaud C, Nahori MA, Soubigou G, Bécavin C, Laval L, Lechat P, Smokvina T, Langella P, Lecuit M, Cossart P. Impact of lactobacilli on orally acquired listeriosis. Proc Natl Acad Sci. 2012;109:16684–9.CrossRef
28.
Zurück zum Zitat Wang Y,Andrews M,Yang Y,Lang S,W Jin J,Cameron-Vendrig A, Zhu G, Reheman A, Ni H. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012;12: 126–132. Wang Y,Andrews M,Yang Y,Lang S,W Jin J,Cameron-Vendrig A, Zhu G, Reheman A, Ni H. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012;12: 126–132.
29.
Zurück zum Zitat Salvucci E, Saavedra L, Hebert EM, Haro C, Sesma F. Enterocin CRL35 inhibits Listeria monocytogenes in a murine model. Foodborne Pathog Dis. 2012;9:68–74.CrossRef Salvucci E, Saavedra L, Hebert EM, Haro C, Sesma F. Enterocin CRL35 inhibits Listeria monocytogenes in a murine model. Foodborne Pathog Dis. 2012;9:68–74.CrossRef
30.
Zurück zum Zitat Sengupta R, Altermann E, Anderson RC, McNabb WC, Moughan PJ, Roy NC. The role of cell surface architecture of lactobacilli in host-microbe interactions in the gastrointestinal tract. Mediat Inflamm. 2013;2013:1–16. https://doi.org/10.1155/2013/237921. Sengupta R, Altermann E, Anderson RC, McNabb WC, Moughan PJ, Roy NC. The role of cell surface architecture of lactobacilli in host-microbe interactions in the gastrointestinal tract. Mediat Inflamm. 2013;2013:1–16. https://​doi.​org/​10.​1155/​2013/​237921.
31.
Zurück zum Zitat Becattini S, Littmann ER, Carter RA, Kim SG, Morjaria SM, Ling L, et al. Commensal microbes provide first line defense against Listeria monocytogenes infection. J Clin Exp Med. 2017;214:1973–89. Becattini S, Littmann ER, Carter RA, Kim SG, Morjaria SM, Ling L, et al. Commensal microbes provide first line defense against Listeria monocytogenes infection. J Clin Exp Med. 2017;214:1973–89.
32.
Zurück zum Zitat Banerjee SP, Dora KC, Chowdhury S. Detection, partial purification and characterization of bacteriocin produced by Lactobacillus brevis FPTLB3 isolated from freshwater fish. Int J Food Sci Technol. 2013;50:17–25.CrossRef Banerjee SP, Dora KC, Chowdhury S. Detection, partial purification and characterization of bacteriocin produced by Lactobacillus brevis FPTLB3 isolated from freshwater fish. Int J Food Sci Technol. 2013;50:17–25.CrossRef
33.
Zurück zum Zitat Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation. 2006;113:2713–23.CrossRef Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation. 2006;113:2713–23.CrossRef
34.
Zurück zum Zitat Sword C. Mechanisms of pathogenesis in Listeria monocytogenes infection I. Influence of iron J Bacteriol. 1966;92:536–42.PubMed Sword C. Mechanisms of pathogenesis in Listeria monocytogenes infection I. Influence of iron J Bacteriol. 1966;92:536–42.PubMed
35.
Zurück zum Zitat Kim MH, Liu W, Borjesson DL, Curry FRE, Miller LS, Cheung AL, Liu FT, Isseroff RR, Simon SI. Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. J Invest Dermatol. 2008;128:1812–20.CrossRef Kim MH, Liu W, Borjesson DL, Curry FRE, Miller LS, Cheung AL, Liu FT, Isseroff RR, Simon SI. Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. J Invest Dermatol. 2008;128:1812–20.CrossRef
36.
Zurück zum Zitat Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Anastasi J, Weitz J. Hematology: basic principles and practice. 6th ed, Elsevier Health Sciences. 2013. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Anastasi J, Weitz J. Hematology: basic principles and practice. 6th ed, Elsevier Health Sciences. 2013.
Metadaten
Titel
Antilisterial efficacy of Lactobacillus brevis MF179529 from cow: an in vivo evidence
verfasst von
Ayesha Riaz
Saleha Noureen
Iram Liqat
Muhammad Arshad
Najma Arshad
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Complementary Medicine and Therapies / Ausgabe 1/2019
Elektronische ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2444-5

Weitere Artikel der Ausgabe 1/2019

BMC Complementary Medicine and Therapies 1/2019 Zur Ausgabe